In each study population, followup questionnaires were sent at 6 and 12 months after randomization and every 12 months thereafter requesting information about development of relevant study end points including cataract and AMD and participant compliance with study medications. Reported diagnoses of cataract and AMD are confirmed by medical record review. The primary analysis for the randomized studies will be incidence of AMD or cataract in the treatment and placebo groups. Survival analysis will be used to determine whether there is a difference in time to AMD or cataract diagnosis.